MRK News 57.77 04/22/2014 18:11:06 Merck & Company (MRK)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 57.77 $MRK

Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - 34 mins ago
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....

A Doozy of a Pharma Rumor
Brian Orelli, The Motley Fool - Motley Fool - 40 mins ago
The latest health care acquisition rumor is a doozy. According to multiple news outlets, Pfizer was in talks with AstraZeneca to acquire the company for over $100 billion, although the companies apparently broke off talks. Interestingly, this...

Pharma deals give stocks a lift
By The Associated Press - AP - Tue Apr 22, 10:55AM CDT
LONDON (AP) — A flurry of deals in the pharmaceutical sector helped to shore up global stock markets on Tuesday.

Novartis, Glaxo Swap Units; Lilly Buying Animal Biz
at Investor's Business Daily - Tue Apr 22, 10:49AM CDT
Big pharmas Novartis (NVS), GlaxoSmithKline (GSK) and Eli Lilly (LLY) announced a massive exchange of business units Tuesday morning in a set of deals with a total value of more than $28 billion. Novartis and Glaxo rose on the stock market today,...

Next Resistance Level for Merck (MRK) is $57.88
Comtex SmarTrend(R) - Tue Apr 22, 9:37AM CDT
Shares of Merck (NYSE:MRK) opened today above their pivot of $56.98 and have already reached the first level of resistance at $57.57. Investors may be interested in a cross of the next upside pivot targets of $57.88 and $58.78.

Stock Market News for April 22, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 9:06AM CDT
Benchmarks ended in the green zone yesterday as investors were encouraged by better-than-expected corporate earnings results

Why Johnson & Johnson Is Outperforming the Dow
George Budwell, The Motley Fool - Motley Fool - Tue Apr 22, 8:30AM CDT
After setting record highs in 2013, the Dow Jones Industrials   has largely traded sideways so far in recent months, down just  0.20% in 2014. Given the general weakness among health care stocks of late, you might suspect that pharma companies have...

Global Human Reproductive ((Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) Technologies Market 2013-2019
M2 - Tue Apr 22, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcxdpd/human) has announced the addition of the "Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs). The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. The global human reproductive technologies market is categorized into the following segments: Infertility Drugs - Gonal-f (recombinant follitropin alfa) - Follistim AQ (follitropin beta) - AndroGel (testosterone) - Testim (testosterone) - Viagra (sildenafil citrate) - Cialis (tadalafil) - Levitra/Staxyn (vardenafil) Infertility Procedures - In Vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI) - Zygote Intrafallopian Transfer (ZIFT) - Gamete Intrafallopian Transfer (GIFT) - Intrauterine Insemination (IUI) Contraceptive Technologies - Drugs - - Oral Contraceptive Pills - - Contraceptive Injectables - - Topical Contraceptives - Devices - - Male Contraceptive Devices (Male Condoms) - - Female Contraceptive Devices Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Human Reproduction Technologies Market, by Infertility Treatment - Global Human Reproductive Technologies Market, by Contraceptive Technologies - Global Human Reproductive Technologies Market Revenue, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/bcxdpd/human

Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:45AM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Global Ankylosing Spondylitis (Bekhterev's Disease) Therapeutcis Pipeline Review 2014 (25 Companies & 16 Drug Profiles)
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zqc5nl/ankylosing) has announced the addition of the "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - Piramal Enterprises Limited - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - Sandoz Inc. - Celgene Corporation - Panacea Biotec Limited - Viropro Inc. - Avesthagen Limited - Shanghai Celgen Bio-Pharmaceutical Co., Ltd. - Biosidus S.A. - Genor BioPharma Co., Ltd. - Aprogen, Inc. - Inbiopro Solutions Pvt. Ltd. - Curaxys, S.L. - Innovent Biologics, Inc. - PanPharmaceuticals USA, Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd - Pharmapraxis Drug Profiles - BI-655066 - IBI-303 - IBPM-004-AM - IBPM-005-IX - INV-17 - ND-007 - P-979 - adalimumab biosimilar - apremilast - etanercept biosimilar - etoricoxib - infliximab biosimilar - infliximab biosmiliar - ixekizumab - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/zqc5nl/ankylosing

Botox maker Allergan draws bid from Valeant
By KEN SWEET and MATTHEW PERRONE - AP - Mon Apr 21, 11:03PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals is teaming up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.

Dow Climbs As Pharma Stocks Jump, but Will Drug M&A Hurt UnitedHealth?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 21, 8:04PM CDT
The Dow Jones Industrials rose more than 40 points Monday as investors continued to ride the wave of enthusiasm that has accompanied the beginning of earnings season. Leading the way higher for the Dow were Pfizer and Merck , which gained 2%...

Valeant to bid for Botox maker Allergan
By KEN SWEET and MATTHEW PERRONE - AP - Mon Apr 21, 7:08PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $40 billion.

Pfizer, Inc. Rebuffed: Is AstraZeneca plc Worth Another Try?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Big-time pharma mergers have had a mixed track record, with large combinations often leading to significant cost reductions (and firings) in sales and administration but at the cost of large disruptions to R&D. Pfizer is apparently not afraid...

Merck Rises 1.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 1.38% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.40 to a high of $57.30. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.00 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Merck among NASA Cargo Launching to Space Station
PR Newswire - Mon Apr 21, 3:15PM CDT
When the SpaceX-3 cargo resupply mission launched to the International Space Station April 14, an experiment designed by Merck Research Laboratories of Kenilworth, N.J., was among the cargo headed to space.

Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.

Interesting May Stock Options For MRK
at The Street - Mon Apr 21, 11:08AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the May...

Pfizer, AstraZeneca Rise On Report Of Merger Talks
at Investor's Business Daily - Mon Apr 21, 10:13AM CDT
Big pharmas Pfizer (PFE) and AstraZeneca (AZN) were both up in early trading on the stock market today after word got out Sunday that Pfizer had offered $101 billion to buy its rival. Citing unnamed sources, the U.K.'s Sunday Times said that the two...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 81

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 185

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 236

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 36

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Fannie Mae Reports Strong Financial Update for Third Quarter

Updated Category News Views 81

Fannie Mae Reports Impressive Third Quarter Financial Results Fannie Mae has recently announced its financial performance for the third quarter of the year, marking a significant achievement with a net income of $4 billion. This statement underscores Fannie Mae's resilience and strategic efforts in the ongoing housing market. These results were disclosed alongside the...

Continue Reading
Willdan's Innovative Energy Design Assistance for Seattle

Updated Category News Views 51

Willdan Partners with Seattle for Energy Design Innovation Willdan Group, Inc. (NASDAQ: WLDN) is thrilled to announce that it has entered into a significant four-year contract to implement the Seattle City Light Energy Design Assistance Program. This initiative is a vital step toward enhancing sustainability in the development of multifamily and commercial buildings. With...

Continue Reading
Nikola Corporation Achieves Record Hydrogen Truck Deliveries

Updated Category News Views 79

Nikola Corporation Reports Impressive Third Quarter Results Nikola Corporation (NASDAQ: NKLA) has announced its third-quarter results, showcasing remarkable progress in its hydrogen fuel cell electric vehicle (FCEV) segment. The company registered a record 88 wholesale deliveries of hydrogen FCEVs, marking a 22% increase from the previous quarter. This significant growth...

Continue Reading
Tempest Therapeutics (TPST) Faces Major Stock Decline Today

Updated Category News Views 295

Understanding the Significant Decline of Tempest Therapeutics Stock Tempest Therapeutics Inc (NASDAQ: TPST) is experiencing a notable decrease in share value today. The sharp decline follows the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Understanding the implications of this acquisition is crucial for investors and...

Continue Reading
FHU's Leadership Program Graduates First Cohort

Updated Category News Views 35

A New Dawn for School Leadership In the world of education, fresh thinking and dynamic leadership can often feel as profound as breakthroughs in any field. Today, we're celebrating a step in that direction. Freed-Hardeman University (FHU) in the heartland of Tennessee is marking a grand milestone. The university just rolled out its first cohort of graduates from the...

Continue Reading